Skip to main content
. Author manuscript; available in PMC: 2013 Oct 1.
Published in final edited form as: Spine (Phila Pa 1976). 2012 Oct 1;37(21):1819–1825. doi: 10.1097/BRS.0b013e31824ee8f7

Figure 4. Pharmacologic suppression of IKK/NF-κB activation ameliorates age-associated disc proteoglycan loss and histopathologic changes.

Figure 4

Figure 4

Figure 4

A, 8K-NBD peptide structure and amino acid sequence (top) and 8K-NBD treatment regimen (bottom). Ercc1-/Δ mice were treated with 10 mg 8K-NBD per kg body weight three times per week intraperitoneally starting from 5 wks of age until 20 wks of age. B, Safranin O and H&E histological staining of disc sections of 8K-NBD-treated Ercc1-/Δ mice and untreated Ercc1-/Δ mice and WT control. Endplate (EP), nucleus pulposus (NP), and annulus fibrosus (AF) are indicated. Red, safranin O staining of proteoglycan. EP cellularity (thick arrow) and NP matrix density (thin arrow) are indicated. C, DMMB assay for total GAG of NP tissue (left graph) and proteoglycan synthesis as measured by 35S incorporation by disc organotypic culture (right graph). NT, not treated. # denotes p < 0.05.